Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Change in Accured Expenses (2017 - 2022)

Arcus Biosciences has reported Change in Accured Expenses over the past 6 years, most recently at $23.5 million for Q3 2022.

  • For Q3 2022, Change in Accured Expenses rose 537.12% year-over-year to $23.5 million; the TTM value through Sep 2022 reached $18.3 million, up 134.38%, while the annual FY2021 figure was $10.1 million, 120.73% up from the prior year.
  • Change in Accured Expenses for Q3 2022 was $23.5 million at Arcus Biosciences, up from -$1.8 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $23.5 million in Q3 2022 and troughed at -$8.5 million in Q1 2022.
  • A 5-year average of $1.6 million and a median of $410000.0 in 2018 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: crashed 22337.5% in 2018 and later soared 15800.0% in 2020.
  • Year by year, Change in Accured Expenses stood at $1.6 million in 2018, then increased by 6.98% to $1.7 million in 2019, then surged by 60.14% to $2.7 million in 2020, then skyrocketed by 85.61% to $5.1 million in 2021, then soared by 364.0% to $23.5 million in 2022.
  • Business Quant data shows Change in Accured Expenses for RCUS at $23.5 million in Q3 2022, -$1.8 million in Q2 2022, and -$8.5 million in Q1 2022.